Our next publication date will be on 3 october, 2022 instead of 30 september, 2022.
Dear respected authors,
if you can't find our response then please search our mail in your spam box and communicate with us to the following mail as well: email@example.com
05 Oct 2022
30 Sep 2022
Azerbaijan medical journal (ISSN: 0005-2523) - is a scopus indexed journal since 1961. The publisher of the journal is Izdatel'stvo Elm by WHO Office in Azerbaijan. Azerbaijan medical journal (AMJ) is also UGC approved. The journal publishes general medicine, health science, psychological, pharmaceutical journals and so on.
Aim and Scope
Azerbaijan Medical Journal
Azerbaijan Medical Journal (ISSN: 0005-2523) - is a peer-reviewed journal. The journal seeks to publish original research articles that are hypothetical and theoretical in its nature and that provide exploratory insights in the following fields but not limited to.
Azerbaijan Medical Journal
Study of the Predictive factors for conversion of Laparoscopic Cholecystectomy to Open Cholecystectomy
The Impact of Vitamin D Deficiency on Some Immunomodulatory Markers in Pregnant Women with Threatened Abortion
THE POTENTIAL ROLE OF HYDROXYCHLOROQUINE IN MODULATING INFLAMMATORY RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS
HISTOPATHOLOGICAL EFFECT IN EYE AND CALCIFICATION HYDROCEPHALUS OF BRAIN FETUSES OF WHITE ALBINO WISTAR RAT INFECTED WITH TOXOPLASMA GONDII ISOLATED FROM THE EMBRYO OF ABORTED SHEEP
Esomeprazole is a proton pump inhibitor (PPIs) successfully used to inhibit gastric acid secretion and treat peptic ulcers and other acid-related disorders. However, the studies of the effect of esomeprazole on liver enzymes are limited. This study aims to investigate the effect of esomeprazole on liver enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphates (ALP) in peptic ulcer patients. Twenty-nine omeprazole users and twenty-four health control were recruited from outpatient clinics. Serum levels of liver enzymes Alanine transferase (ALT), aspartate transferase (AST), and alkaline phosphates (ALP) were evaluated at least 2 months after the medication use. Serum levels of ALP (74.31± 19.63 U/L, P<0.0001) were significantly higher in esomeprazole users compared to non-users. While serum levels of ALT (16.07± 6.3 U/L, P=0.008) were significantly lower in esomeprazole users. Serum AST levels (18.86±6.4 U/L, p= 0.192) were not changed between the 2 groups. Whilst this study did not confirm the hepatotoxicity of esomeprazole on the liver, it could indicate that esomeprazole might affect the liver. Further research is required to determine whether esomeprazole is hepatotoxic or not.